Evommune (EVMN) Cash from Financing Activities (2024 - 2026)

Evommune (EVMN) has 3 years of Cash from Financing Activities data on file, last reported at $117.1 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 77146.71% year-over-year to $117.1 million in Q1 2026; TTM through Mar 2026 was $323.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $220.8 million, up 346.72% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $117.1 million, down from $156.8 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for EVMN reached as high as $156.8 million in Q4 2025 and fell as low as -$152000.0 in Q1 2025.
• Historically, Cash from Financing Activities has averaged $80.9 million across 3 years, with a median of $83.4 million in 2024.
• Across the five-year window, Cash from Financing Activities soared 215.58% in 2025 and surged 77146.71% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at $49.7 million in 2024, then surged by 215.58% to $156.8 million in 2025, then declined by 25.33% to $117.1 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $117.1 million in Q1 2026, $156.8 million in Q4 2025, and -$152000.0 in Q1 2025.